

Role of Fecal Lactoferrin as a Non Invasive Biomarker
in Diagnosis of Inflammatory Bowel Disease and
Assessment of Disease Activity

Thesis

Submitted for Partial Fulfillment of Master Degree in
Internal Medicine

By

Ahmed Mohamed Naguib

MB.B.Ch. Ain Shams University, 2011

Under Supervision of

Prof. Dr. Mohamed M. Makhlouf

*Professor of Internal Medicine and Gastroenterology
Faculty of Medicine, Ain Shams University*

Asst. Prof. Dr. Wael A. Yousry

*Assistant professor of Internal Medicine and
Gastroenterology
Faculty of Medicine, Ain Shams University*

Dr. Shereen Abo Bakr Saleh

*Lecturer of Internal Medicine and Gastroenterology
Faculty of Medicine, Ain Shams University*

Faculty of Medicine
Ain Shams University

2015



Acknowledgements



*First of all, I would like to express my deep gratitude to **ALLAH** for his care and generosity throughout my life and for blessing this work, until it has reached its end..*

*I would like to express my deep gratitude and appreciation to **Prof. Dr. Mohamed Marei Makhlouf**, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for his creative suggestions, fatherhood and encouragement throughout this work, besides the tremendous effort he has done in the revision of the whole work. It is a great honor to work under his guidance and supervision.*

*I wish also to express my sincere gratefulness to **Ass. Prof. Dr. Wael Ahmed Yosry**, Assistant Professor of Internal Medicine, Faculty of Medicine, Ain Shams University for his guidance, continuous supervision, sincere assistance and continuous support during all stages of this work.*

*I would like also to express my deep appreciation and gratitude to **Dr. Shereen AbuBakr Saleh**, Lecturer of Internal Medicine, Faculty of Medicine, Ain Shams University, for her overwhelming help, continuous directions and support throughout the whole work.*

Last but not least, I dedicate this work to my family (my father, mother, brother and sister), my colleagues whom without their sincere emotional support, help & pushing me forward, this work would not have ever been completed.

Ahmed Mohamed Naguib



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا

عِلْمَ لَنَا إِلَّا مَا

عَلَّمْتَنَا إِنَّكَ أَنْتَ

الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة آية (٣٢)

List of Contents

Title	Page No.
List of Tables.....	i
List of Figures	iii
List of Abbreviations.....	v
Introduction	1
Aim of the Work.....	4
Review of Literature	
• Inflammatory Bowel Diseases	5
• Irritable bowel syndrome	49
• Fecal Markers.....	80
Patients and Methods	96
Results	104
Discussion	120
Summary	127
Conclusion.....	130
Recommendations	131
References	132
Arabic Summary.....	--

List of Tables

Table No.	Title	Page No.
Table (1):	Mayo endoscopic score	30
Table (2):	Fecal markers in clinical use.....	81
Table (3):	Characteristics of the studied subjects as regard the gender.....	104
Table (4):	Characteristics of the studied subjects as regard age and body mass index (BMI).	105
Table (5):	Descriptive analysis of patients with inflammatory bowel disease (group 1) regarding disease activity.....	106
Table (6):	Descriptive analysis of different laboratory parameters in all subjects.....	107
Table (7):	Comparison between different study groups regarding renal profile.....	108
Table (8):	Comparison between different study groups regarding liver profile.	109
Table (9):	Comparison between different study groups regarding total serum proteins and albumin.....	110
Table (10):	Comparison of p-values (significance) between every 2 studied groups regarding total serum proteins and serum albumin.	110
Table (11):	Comparison between different study groups regarding stool WBC, RBC counts.....	111

List of Tables (Cont...)

Table No.	Title	Page No.
Table (12):	Comparison of p-values (significance) between every 2 studied groups regarding stool WBC, RBC counts.	111
Table (13):	Comparison between different study groups regarding hematological parameters.	112
Table (14):	Comparison of p-values (significance) between every 2 study groups regarding total WBC count, ESR, CRP.	112
Table (15):	Comparison between different study groups regarding fecal Lactoferrin levels.	113
Table (16):	Detailed comparison between different study groups regarding fecal Lactoferrin levels.	114
Table (17):	Comparison of fecal lactoferrin levels in patients with inflammatory bowel disease at different stages of activity.	115
Table (18):	Correlation between FLA levels with other laboratory parameters in patients with inflammatory bowel disease and those with irritable bowel syndrome.	116
Table (19):	Diagnostic value of FLA levels in discriminating patients with IBD patients from IBS patients.	117
Table (20):	Diagnostic value of FLA levels in discriminating IBD patients from healthy subjects.	118
Table (21):	Diagnostic value of FLA levels in discriminating IBS patients from healthy subjects.	119

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Pathway of the mucosal inflammation underlying inflammatory bowel disease	15
Figure (2):	Conceptual framework for the pathogenesis of IBD	16
Figure (3):	Crohn's Disease Activity Index	36
Figure (4):	Current and emerging therapies for inflammatory bowel disease (IBD).....	37
Figure (5):	Summary of the main classical and novel approaches for IBD treatment.....	43
Figure (6):	Manning criteria for IBS.	61
Figure (7):	Rome 3 criteria for diagnosis of IBS	62
Figure (8):	Alarm features of IBS	64
Figure (9):	DD of IBS-D subtype.....	66
Figure (10):	An overview of the main sources and potential uses of the various faecal markers	82
Figure (11):	Reference ranges of fecal calprotectin	85
Figure (12):	Receiver Operator Curve Analysis was done to estimate the diagnostic value of FLA levels in discriminating patients with IBD from IBS patients.	117

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (13):	Receiver Operator Curve Analysis was done to estimate the diagnostic value of FLA levels in discriminating patients with IBD from healthy subjects.....	118
Figure (14):	Receiver Operator Curve Analysis was done to estimate the diagnostic value of FLA levels in discriminating patients with IBS from healthy subjects.....	119

List of Abbreviations

Abb.	Full word
5-ASA.....	5-aminosalicylate
5-HT	Serotonin
6MP	6-mercaptopurine
AIDS.....	Adult immunodeficiency syndrome
AIEC	Adherent and invasive <i>E. coli</i>
ASCA	Anti-Saccharomyces cerevisiae antibodies
AZA.....	Azathioprine
CBC	Complete blood cell
CD	Crohn's disease
CDEIS.....	Crohn's disease Endoscopic Index Of Severity
COPD	Chronic obstructive pulmonary disease
CRH.....	Corticotropin-releasing hormone
CRP.....	C-reactive protein
CT	Computed tomography
DBE	Double balloon enteroscopy
DCs	Dendritic cells
ELISA.....	Enzyme linked immunosorbent assay
ESR.....	Erythrocyte sedimentation rate
FBC.....	Full blood count
FC	Fecal calprotectin
FDA	Food and Drug Administration
FGIDs	Functional gastrointestinal disorders
FL	Fecal Lactoferrin
FLA.....	Fecal Lactoferrin assay

List of Abbreviations (Cont...)

Abb.	Full word
FODMAPs	Fermentable oligo-, di-, and monosaccharides and polyols
GI.....	Gastrointestinal
HADS	Hospital anxiety and depression scale
HSCT	Hematopoietic stem cell transplantation
IBD	Inflammatory bowel disease
IBS.....	Irritable Bowel Syndrome
IBS-C	Irritable bowel syndrome costipation subtype
IBS-D.....	Irritable bowel syndrome diarrhea subtype
IBS-M	Irritable bowel syndrome mixed subtype
IFN.....	Interferon
IL	Interleukin
IPAA.....	Ileal-pouch anal anastomosis
JAK.....	Janus kinase
M2PK	M2-pyruvate kinase
MCV	Mean corpuscular volume
MDP	Muramyl dipeptide
MMPs	Metalloproteinases
MPOs.....	Myeloperoxidases
MRI.....	Magnetic resonance imaging
MSC.....	Mesenchymal stromal cells
MTX	Methotrexate
NCCDS.....	Landmark National Cooperative Crohn's Disease Study
NF	Nuclear Factor
NK	Natural killer cells
NOD2	Nucleotide-binding oligomerization domain containing 2

List of Abbreviations (Cont...)

Abb.	Full word
NSAIDs	Nonsteroidal anti-inflammatory drugs
pANCA.....	Perinuclear antineutrophil cytoplasmic antibodies
PEG.....	Polyethylene glycol
PHQ	Patient health questionnaire
PI-IBS	Post infectious irritable bowel syndrome
PMN	Polymorphonuclear leucocytes
PMN-e	Polymorphonuclear neutrophil-elastase
PRRs	Pattern recognition receptors
RAGE	Receptor of advanced glycation end products
SBFT.....	Small bowel follow through
SeHCAT	Selenium homocholic acid taurine
SERT	Serotonin reuptake transporter
SES-CD	Simple Endoscopic Score For Crohn's Disease
SIBO	Small intestinal bacterial overgrowth
SSRIs	Selective serotonin reuptake inhibitors
TCAs.....	Tricyclic antidepressants
Th	T-helper cell
TNF.....	Tumor necrosis factor
UC	Ulcerative Colitis
UCCIS	Ulcerative Colitis Colonoscopic Index of Severity
UCDAI	Ulcerative colitis disease activity index
UCEIS.....	Ulcerative Colitis Endoscopic Index of Severity
US	Ultrasonography
WBC	white blood cell
WGO.....	World Gastroenterology Organization

INTRODUCTION

Inflammatory bowel diseases (IBD) including ulcerative colitis (UC) and Crohn's Disease (CD) are chronic inflammatory disorders of the gastrointestinal tract identified by episodes of relapse and remission (**Ponder *et al.*, 2013**).

IBD had uncertain etiology; it imagined to be caused by interplaying among different environmental, genetic and immunologic factors (**Jussila *et al.*, 2012**). Previous studies revealed that different factors such as infectious diseases and nutrition during infancy, tonsillectomy, appendectomy, lifestyle factors and diet, domestic hygiene, refrigeration of food, time scales of socioeconomic evolution, drugs (nonsteroidal anti-inflammatory drugs [NSAIDs] and oral contraceptive pills), smoking, intestinal pathogens, and measles vaccination play a role in IBD (**Vahedi *et al.*, 2009**).

UC involves primarily the colon, and the symptoms include continuous or repeated blood in the stool and diarrhea. In contrast, CD may involve the entire gastrointestinal tract including the small intestine, colon, esophagus, and stomach. Perianal lesions are frequently observed in patients with CD. A discrepancy between clinical symptoms and endoscopic severity is observed in the clinical setting. Thus, endoscopic assessment is critical for the management of IBD. The assessment of the extent and severity of the disease is also important for decision making in the medical treatment of IBD (**Naganuma *et al.*, 2015**).

In adult population, chronic diarrhea is a relatively common condition and often poses a diagnostic challenge despite its frequency (**Limburg *et al.*, 2000**). In fact, diagnosis based on initial history and physical examination occurred only in about one-third of all patients with chronic diarrhea. One of the most frequent causes of chronic diarrhea in adults is probably irritable bowel syndrome (IBS) (**Delvaux *et al.*, 2003**).

Patients with IBD and irritable bowel syndrome (IBS) share many clinical symptoms, including abdominal pain, diarrhoea and generalized malaise. A considerable proportion of patients, especially those presenting in primary care, will have functional disorders with no need for invasive examinations. In many cases, IBD and IBS cannot be separated from each other exclusively on the basis of clinical symptoms. Until recently, colonoscopy was required to rule out IBD. However, more than half of patients with symptoms suggesting IBD will have negative endoscopy and be diagnosed with IBS (**Van de Vijver *et al.*, 2012**).

Fecal measurements of potential biomarkers are noninvasive diagnostic tests for intestinal mucosal inflammation and may correlate well with disease activity. Several neutrophil-granular proteins released by activated neutrophils may constitute fecal markers of intestinal inflammation, including lactoferrin (LF), calprotectin (Cal), polymorphonuclear neutrophil-elastase (PMN-e), and lysozyme (Lys), with calprotectin and lactoferrin appearing to be the most promising surrogate biomarkers (**Langhorst *et al.*, 2005**).

Lactoferrin is an iron-binding protein; it covers most mucosal surface and interacts with exocrine organs or substances including parotid, tears, vaginal discharge, articular synovia, and latex (**Kane *et al.*, 2003**). It is a component of neutrophil granulocytes and activated in acute inflammation. Fecal lactoferrin increases significantly as infiltration of neutrophils in intestinal tracts (**Desai *et al.*, 2007**). It is stable for 5 days in feces whenever repeating freeze thawing (**Joishy *et al.*, 2009**).

Studies investigating whether FL can be used as a noninvasive marker to distinguish IBD from non inflammatory conditions, especially IBS have yielded variable results (**Kopylov *et al.*, 2014**).

During inflammation, lactoferrin is released by the injured tissue and has been found to modulate inflammation and act in the defense against infections as a part of the innate immune system (**Angriman *et al.*, 2007**). It is resistant to degradation and proteolysis, and unaffected by freeze thaw cycles, making it a useful biomarker (**Mendoza *et al.*, 2009**). As such, it is an ideal marker for intestinal inflammation. However, like calprotein it is unspecific for CD and UC, but can distinguish active IBD from inactive IBD and irritable bowel syndrome (**Schoepfer *et al.*, 2008**).

AIM OF THE WORK

The aim of this study is to assess the role of fecal lactoferrin as a non invasive biomarker in diagnosis of inflammatory bowel disease and assessment of disease severity.